Reclast Every 5 Years? What a New Study Really Says About Long-Term Bisphosphonate Use

What if there was a way to use a bisphosphonate drug like Reclast (zoledronate) as a long-term fracture prevention plan?

That is exactly what a newer study suggests. And at first glance, it sounds like the “easy button” for osteoporosis. One infusion now. Maybe one more in five years. Then a decade of protection.

If that were true for everyone, I could stop talking about protein, strength training, impact work, sleep, hormones, and the whole lifestyle plan.

But the truth is more complicated.

This post breaks down what the study did, what it found, and why the results are real and still not a “drug-only” solution for most people.

First, a quick reminder: what bisphosphonates do

Bisphosphonates are anti-resorptive drugs. That means they slow down bone breakdown.

They do this by binding to bone. When osteoclasts (the bone breakdown cells) try to resorb bone, they take in the drug and get shut down. That leads to lower bone resorption and higher bone density in the short term.

That can be helpful. But there is a tradeoff.

Bone is not supposed to be frozen. Bone is living tissue. It needs turnover and remodeling to stay strong.

If you suppress turnover too hard for too long, you can raise the risk of rare but serious issues, like:

• atypical femur fractures
• osteonecrosis of the jaw

That is part of why guidelines often recommend stopping after 3 years for IV therapy or 3–5 years for oral therapy, followed by a “drug holiday.”

The big problem is that drug holidays are messy. How long should they be? When do you restart? Which drug do you restart? Do you switch to an anabolic? There is not one clean answer.

That is why a study about long-term infrequent dosing is so interesting.

‍

The study: what did they actually test?

This trial was published in the New England Journal of Medicine and included a little over 1,000 women.

The age group was important:

• women aged 50 to 60

And also this key point:

• their T-scores were greater than -2.5

So these women did not have osteoporosis at baseline. Some had low bone density, but they were not in the osteoporosis range.

The dosing plan

The study used zoledronate (Reclast) 5 mg:

• Group A: zoledronate at baseline and at year 5 (two doses total)
• Group B: zoledronate at baseline and placebo at year 5 (one dose total)
• Group C: placebo at baseline and placebo at year 5 (no doses)

Then they followed the women for 10 years.

What did they measure?

They did several useful things:

• spine x-rays to look for morphometric vertebral fractures
• DEXA scans at 5 and 10 years
• bone turnover markers (P1NP and CTX)

That last part matters. I love when studies include turnover markers, because it shows what is happening under the hood.

The fracture result: yes, it reduced vertebral fractures

Over 10 years:

• two-dose group: 6.3% had morphometric vertebral fractures
• placebo group: 11.1% had morphometric vertebral fractures
• one-dose group: not much different than placebo

So the two-dose approach did reduce vertebral fracture outcomes over 10 years.

That is a real outcome. And it is statistically meaningful.

If you are in a group that truly needs this approach, that is a win.

But we also need to be honest about what “vertebral fracture” means in these trials.

A key detail: these were “morphometric” vertebral fractures

Morphometric fractures are found by x-ray measurement. It means a vertebra looks compressed on imaging.

Some of these fractures are painful and obvious. Some are silent. They are still relevant. But they are not the same as a hip fracture that sends someone to the hospital.

So yes, a reduction here matters. But it is still not the entire story.

Bone density results: spine looked better than hip (as expected)

Now let’s talk DEXA.

This was the pattern:

• placebo group lost bone over time
• zoledronate helped protect bone
• the spine response was stronger than the hip response

That is not surprising. Bisphosphonates usually show stronger effects in trabecular-rich bone (spine) than cortical-heavy bone (hip).

Placebo group (expected loss)

In the placebo group, by year 10, lumbar spine bone density dropped about 6%.

That is what you expect in this age group when you exclude hormone therapy and other strong bone tools.

One dose vs two doses

This is where it gets interesting.

The one-dose group increased early, then started to decline over time.

The two-dose group increased early and held better, but it did not keep climbing forever.

In the hip, even the two-dose group drifted back toward baseline by year 10.

So what does that tell us?

It suggests there may be a ceiling effect. The drug helps, but it does not keep stacking gains forever.

Bone turnover markers: the “hidden” story

This is the part that matters most to me.

They measured:

• P1NP (bone building marker)
• CTX (bone breakdown marker)

And yes, you see what you expect:

• CTX drops after dosing
• P1NP also drops after dosing

That second point is the one many people miss.

If you suppress breakdown, you often suppress building too.

Here is the shocking part

Even at 10 years, after a single infusion, bone turnover markers were still suppressed.

Not massively suppressed, but still below baseline.

This tells you how long this drug can stay active in the body.

That matters for consent. If you do not want long-term suppression, you need to know what you are signing up for.

This also explains why “drug holidays” are so confusing. The drug may still be doing something long after you stop taking it.

The ratio issue: why “favorable” markers still don’t mean “building”

If CTX drops more than P1NP, the ratio can look “more anabolic.”

In simple terms:

• if breakdown drops more than building, the body should be “net building,” right?

But in real life, and in drug-treated patients, this is not always true.

Here is why:

There appears to be a threshold where P1NP gets too low. When building is suppressed enough, it does not matter if breakdown is even more suppressed. There just is not enough building activity to keep improving bone over time.

This study supports that concern.

Even with long-term suppression, bone density did not keep climbing. It plateaued, then drifted.

That is not a good sign if you are trying to use this as a 15–20 year “forever plan.”

Does this solve the “long-term drug plan” problem?

It helps. But it does not solve it.

Here is the honest take:

What this study shows (the wins)

• very infrequent zoledronate can reduce vertebral fracture outcomes over 10 years (in this group)
• it can reduce bone loss compared to placebo
• it did not show a dramatic increase in jaw or femur complications in this sample

That is useful.

What this study does NOT show

• it does not show this is the best plan for osteoporosis
• it does not show it works the same in older, frailer women
• it does not show it builds bone indefinitely
• it does not show it replaces lifestyle, hormones, and training

And it has one huge limitation.

The most important limitation: they studied the “wrong” group for most real-world decisions

This study was in women 50 to 60 who did not have osteoporosis.

This is the group that is often most likely to benefit from:

• lifestyle change (because they are still young enough to execute for decades)
• strength training + impact
• protein-forward nutrition
• sleep and stress support
• hormone conversation (because many are candidates)

And the study excluded hormone therapy.

That matters because estradiol is FDA approved for osteoporosis prevention. And in clinical practice, properly used hormone therapy often produces strong bone results in this life stage.

So who is this drug strategy most useful for?

Probably not “the masses” in this age group.

It may be more relevant for:

• older people with a shorter time horizon
• people who cannot do the training and nutrition plan
• people with rapid bone loss that cannot be stabilized
• people with a high risk situation where suppression is needed

The practical takeaway: this is a tool, not the plan

If you want a clean message, here it is:

This study is a win for drug science.
It is not a replacement for a full bone plan.

In the right person, a strategy like “Reclast at baseline + year 5” may reduce fracture risk and protect bone over a decade.

But for many women in their 50s and early 60s, a smarter first-line approach is:

• measure bone early (DEXA or REMS)
• address hormones when appropriate
• build muscle and impact capacity
• improve protein and mineral intake
• track progress with labs and imaging

For most people, that plan is safer long-term and has broader health benefits.

What I would do if you are considering Reclast long-term

If you are thinking about this approach, here are the questions you should ask:

• Do I actually have osteoporosis, or am I in the prevention window?
• What is my fracture risk right now?
• What is my timeline (10 years vs 30 years)?
• Am I able to do strength training and impact work?
• Am I a candidate for hormone therapy?
• What do my bone turnover markers look like now?
• If I take this drug, what is the plan at year 10?

A simple checklist before you commit

• DEXA or REMS baseline
• labs: vitamin D, minerals, bone turnover markers if possible
• fall risk assessment (balance, gait, strength)
• protein intake check
• discussion of hormones if appropriate
• discussion of dental risk and jaw health
• a written plan for “what happens next”

Natural next step (CTA blended)

If you are trying to decide whether drugs belong in your plan, the fastest way to get clarity is to learn the full framework first.

That is why we run a free Bone Health Masterclass. We cover the biggest mistakes we see and the best levers to pull first. You can also bring questions to the live Q&A.

And if you want long-term support, accountability, and community, that is what The OsteoCollective is built for.

FAQ

Can Reclast really last 10 years?

This study suggests a single dose can suppress bone turnover for many years, and a second dose at year 5 can reduce vertebral fracture outcomes over 10 years in a prevention-level population.

Does this mean I can skip lifestyle work?

No. Bone density is only one piece. Muscle, balance, protein intake, hormones, and fall risk still matter. Drugs do not replace those.

Why did hip bone density not improve as much?

Hip bone is more cortical bone and tends to respond less to bisphosphonates than the spine.

Is long-term suppression a problem?

It can be. Bone needs remodeling. Long-term suppression may raise rare risks and may limit long-term gains. This is why long-term planning matters.

Who might benefit most from this approach?

Often older individuals, higher-risk patients, or people who cannot stabilize bone loss through lifestyle and hormones.

Medical disclaimer

This content is for educational purposes only and is not medical advice. Do not start, stop, or change medications without speaking with your physician or qualified healthcare provider. Bisphosphonates can have serious risks and may not be appropriate for everyone, especially people with certain dental issues, kidney problems, or a history of atypical fractures.

‍